Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA

• Main Authors: Mariana M. Lanata, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, Amy Leber
• Format: Article
• Language: English
• Published: Centers for Disease Control and Prevention 2021-06-01
• Series: Emerging Infectious Diseases
• Subjects: Mycoplasma pneumoniae; macrolide sensitivity; macrolide resistance; molecular detection; children; disease severity
• Online Access: https://wwwnc.cdc.gov/eid/article/27/6/20-3206_article
• ISSN: 1080-6040; 1080-6059

Emergence of macrolide-resistant Mycoplasma pneumoniae (MRMp) challenges empiric macrolide therapy. Our goal was to determine MRMp rates and define characteristics of children infected with macrolide-sensitive M. pneumoniae (MSMp) versus MRMp in Ohio, USA. We cultured PCR-positive M. pneumoniae specimens and sequenced M. pneumoniae–positive cultures to detect macrolide resistance mutations. We reviewed medical records to compare characteristics of both groups. We identified 14 (2.8%) MRMp and 485 (97.2%) MSMp samples. Patients in these groups had similar demographics and clinical characteristics, but patients with MRMp had longer hospitalizations, were more likely to have received previous macrolides, and were more likely to have switched to alternative antimicrobial drugs. MRMp-infected patients also had ≈5-fold greater odds of pediatric intensive care unit admission. Rates of MRMp infections in children in central Ohio are low, but clinicians should remain aware of the risk for severe illness caused by these pathogens.